pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ASTRAZENECA · news · pharmadog
← back to ASTRAZENECA
News mentioning ASTRAZENECA
209
stories
28d
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
29d
Scancell plans Neuphoria merger; AstraZeneca wins EU nod for cancer drug
endpoints
Jul 22, 26
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
Jul 22, 26
Crystalys nets $130M more to push gout drug through late-stage tests
biopharma dive
Jul 22, 26
Novartis scraps mid-stage radiopharma asset as Pluvicto soars
biospace
Jul 22, 26
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
Jul 22, 26
Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug
fiercebiotech
Jul 22, 26
AI data becomes sticking point in biopharma dealmaking
biospace
Jul 22, 26
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
biospace
Jul 21, 26
Crystalys mines $130M series B to push gout drug through phase 3
fiercebiotech
Jul 21, 26
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
Jul 21, 26
Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
fiercebiotech
Jul 20, 26
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
fiercebiotech
Jul 20, 26
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
Jul 17, 26
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
fiercebiotech
Jul 16, 26
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
biospace
Jul 16, 26
Updated: Merck beats AstraZeneca to approval for first PCSK9 pill
endpoints
Jul 16, 26
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma
biospace
Jul 15, 26
Merck ADC, in China study, shows potential to replace chemo in lung cancer
biopharma dive
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jul 14, 26
STAT+: Akero team, backed by Fairmount, launches new immunology company
stat
Jul 14, 26
AstraZeneca to take rights to Dizal's lung cancer pill Zegfrovy
endpoints
Jul 13, 26
Agenus surges on study pivot; Apnimed lines up an IPO
biopharma dive
Jul 12, 26
STAT+: Tau in the spotlight at Alzheimer’s conference
stat
Jul 10, 26
STAT+: Roche ends Huntington’s gene-silencing programs
stat
Jul 9, 26
Roche scraps two Ionis-partnered Huntington’s drugs
biopharma dive
Jul 9, 26
Whistleblower takes on health insurance and FDA commissioner candidates
stat
Jul 9, 26
STAT+: ARPA-H launches $160 million effort to develop custom gene editing drugs
stat
Jul 9, 26
STAT+: Prime wins Beam arbitration, clearing path to clinic
stat
Jul 9, 26
STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and more
stat
← prev
page 4 of 7
next →
